Impact of adverse drug reactions (ADR) on systemic therapy in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC). 31. Mai 2010 Marschner, N., Münch, A., Blumenstengel, K., Sauer, U., Müller, L., 2010. Ann Oncol, Abstract 949 21(suppl 8), viii298. doi:10.1093/annonc/mdq525 Abstract